OKYO Pharma (OKYO) announced that, effective immediately, Robert Dempsey will assume the role of CEO. Gary Jacob, Ph.D. will transition to Chief Development Officer and continue to serve as a member of the Board of Directors. Dempsey will join OKYO Pharma immediately as CEO and an executive Board member bringing more than two decades of global ophthalmology experience, including drug development, commercialization, and value-creating strategic transactions. Dempsey previously served as Group Vice President and Head of Global Ophthalmology at Shire.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data
- OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials
- Okyo Pharma chairman acquires 24,551 company shares
- OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain
- Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial